InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research report released on Tuesday morning. The firm issued a sell rating on the stock.

Separately, Piper Sandler restated an overweight rating and issued a $4.50 price target on shares of InspireMD in a research note on Tuesday, September 17th.

InspireMD Stock Down 0.8 %

NSPR opened at $2.64 on Tuesday. The stock has a market capitalization of $65.82 million, a price-to-earnings ratio of -3.47 and a beta of 0.91. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.85. The company has a 50-day simple moving average of $2.81 and a 200 day simple moving average of $2.53.

InspireMD (NYSE:NSPR) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The firm had revenue of $1.74 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same period last year, the business earned ($0.24) earnings per share. Sell-side analysts anticipate that InspireMD will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On InspireMD

An institutional investor recently raised its position in InspireMD stock. Rosalind Advisors Inc. boosted its holdings in InspireMD, Inc. (NYSE:NSPR) by 266.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,513,641 shares of the company’s stock after acquiring an additional 1,827,579 shares during the quarter. InspireMD accounts for approximately 4.6% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 8th biggest holding. Rosalind Advisors Inc. owned 10.08% of InspireMD worth $6,272,000 as of its most recent SEC filing. 44.78% of the stock is currently owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.